Objective To investigate the efficacy of neoadjuvant chemotherapy in patients with stage T3 and T4 rectal cancer and its related influencing factors, and to provide reference for the Locally advanced rectal cancer to choose optimal treatment schemes.Methods Ninetyone patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy from a hospital were selected, and after receiving XELOX chemotherapy, the patients were divided into three groups: complete remission , partial remission and stable disease , according to Response Evaluation Criteria in Solid Tumors.The general characteristics of patients and relevant clinical indicators before and after chemotherapy were collectedto observe the changes of the indicators related to the cancer, and univariate and multivariate analysis were used to analyze the related factors affecting the efficacy of neoadjuvant chemotherapy. Results Of the 91 patients, 18 (19.78%) had complete remission, and 40 (43.96%) with partial remission, 33(36.36%) with stable disease. Multivariate analysis showed that lymph node metastasis before treatment was an independent factor affecting the efficacy of neoadjuvant chemotherapy after adjusting gender (OR=1.731,95%CI: 1.152~2.601).Conclusion Patients with locally advanced rectal cancer can benefit from neoadjuvant therapy, to maximize the efficacy of neoadjuvant chemotherapy, the condition of patients including gender, tumor diameter, and the situation of lymph node metastasis should be considered before chemotherapy.
叶倩,张秋菊,丛雨欣,李称,刘美娜. T3与T4期直肠癌患者新辅助化疗效果比较及影响因素分析[J]. 中国医院统计, 2019, 26(2): 81-84.
Ye Qian, Zhang Qiuju, Cong Yuxin, Li Cheng, Liu Meina. Comparison of the efficacy of neoadjuvant chemotherapy in patients with stage T3 and T4 rectal cancer and analysis of its influencing factors. journal1, 2019, 26(2): 81-84.
[3]SMITH JJ , GARCIAAGUILAR J.Advances and challenges in treatment of locally advanced rectal cancer[J]. J Clin Oncol, 2015, 33(16):1797-1808.
[4]CHOI JH, AHN MJ, RHIM HC, et al. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma[J]. Cancer Res Treat, 2005, 37(5):290-293.
[5]SADA YH, TRAN CAO HS, CHANG GJ,et al.Prognostic value of neoadjuvant treatment response in locally advanced rectal cancer[J]. J Surg Res, 2018(226):15-23.
[6]JIA H, SHEN X, GUAN Y,et al. Predicting the pathological response to neoadjuvant chemoradiation using untargeted metabolomics in locally advanced rectal cancer[J]. Radiother Oncol, 2018, 128(3):548-556.
[7]AGOSTINI M, JANSSEN KP, KIM IJ,et al.An integrative approach for the identification of prognostic and predictive biomarkers in rectal cancer[J]. Oncotarget, 2015, 6(32):32561-32574.
[9]CHAO TB, CHAO TB, LI CF et al.Prognostic significance of DSG3 in rectal adenocarcinoma treated with preoperative chemoradiotherapy[J]. Future Oncology, 2016, 12(12):1457-1467.
[10]PARK CH, KIM HC, CHO YB et al.Predicting tumor response after preoperative chemoradiation using clinical parameters in rectal cancer[J]. World J Gastroenterol, 2011, 17(48):5310-5316.